Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26983410 | 0.86 | SLC6A9 (0.31) | — | |
| SCHEMBL29964834 | 0.86 | — | — | |
| SCHEMBL29964864 | 0.85 | — | — | |
| SCHEMBL29965410 | 0.83 | — | — | |
| SCHEMBL29965105 | 0.78 | — | — | |
| SCHEMBL29964844 | 0.77 | — | — | |
| SCHEMBL29964853 | 0.77 | NAMPT (0.34) | — | |
| SCHEMBL29965177 | 0.77 | DAO (0.33) | — | |
| SCHEMBL29965100 | 0.76 | — | — | |
| SCHEMBL26983404 | 0.75 | ALDH1A1 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12600730-B2 | Substituted cyclopenta[c]pyrroles as ABHD6 antagonists | ONO PHARMACEUTICAL CO., LTD. (JP) | 2026-04-14 | — | — | US | disclosed |
| US-20240270755-A1 | SUBSTITUTED CYCLOPENTA[c]PYRROLES AS ABHD6 ANTAGONISTS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2024-08-15 | — | — | US | disclosed |
| EP-4317153-A1 | ABHD6 ANTAGONIST | ONO Pharmaceutical Co., Ltd. (JP) | 2024-02-07 | — | — | EP | disclosed |
| US-20240010658-A1 | ABHD6 ANTAGONIST | ONO PHARMACEUTICAL CO., LTD. (JP) | 2024-01-11 | — | — | US | disclosed |
| WO-2022211060-A1 | ABHD6 ANTAGONIST | 小野薬品工業株式会社 | 2022-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240010658-A1 | ABHD6 ANTAGONIST | ABHD6, ABHD16A, ABHD12 | IRAK4 3049/4885 |
| US-20240270755-A1 | SUBSTITUTED CYCLOPENTA[c]PYRROLES AS ABHD6 ANTAGONISTS | ABHD6, ABHD16A, PITHD1 | IRAK4 4258/4885 |
| US-12600730-B2 | Substituted cyclopenta[c]pyrroles as ABHD6 antagonists | ABHD6, ABHD16A, HDHD5 | IRAK4 3089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.